胃食管癌.pdf

1、Sunday,March 2,2025ModeratorNeil Love,MDFacultyThomas A Abrams,MDPrithviraj Bose,MDNatalie S Callander,MDRamaswamy Govindan,MDShilpa Gupta,MDYelena Y Janjigian,MDAhmed Omar Kaseb,MD,CMQ Samuel J Klempner,MD Andrew T Kuykendall,MD Christopher Lieu,MDStephen V Liu,MD Thomas Martin,MD Paul E Oberstein,

2、MD,MSPhilip A Philip,MD,PhD Kanwal Raghav,MD Jonathan E Rosenberg,MD Module 15:Immunotherapy and Other Nontargeted Approaches for NSCLCManagement of Nonmetastatic NSCLC without a Targetable Mutation Dr GovindanFirst-and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation Dr LiuModu

3、le 15:Immunotherapy and Other Nontargeted Approaches for NSCLCManagement of Nonmetastatic NSCLC without a Targetable Mutation Dr GovindanFirst-and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation Dr LiuImmunotherapy and Other Nontargeted Approaches for NSCLCRamaswamy Govindan M.

4、D.Alvin J Siteman Cancer Center Washington University School of Medicine St.LouisDisclosuresNo relevant conflicts of interest to disclose.First Phase III:CheckMate 816CheckMate 816 Trial 4-Year Update:Event-Free Survival(EFS)and Overall Survival(OS)with Neoadjuvant Nivolumab and Chemotherapy versus

5、Chemotherapy AloneSpicer J et al.ASCO 2024;Abstract LBA8010.EFSFinal Analysis of CheckMate 816 Demonstrates Statistically Significant and Clinically Meaningful OS Improvement for Patients with Resectable NSCLCPress Release:February 19,2025The final analysis of overall survival(OS)from the Phase 3 Ch

6、eckMate 816 study,which evaluated nivolumab in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable NSCLC(tumors 4 cm or node-positive),demonstrated a statistically significant and clinically meaningful improvement in OS,a key secondary endpoin